Most Active

APLD 17,410
FUBO 35,063
BLRX 4,846
TLRY 33,223
PTON 17,333
LCID 86,441
ADTX 9,037
HSDT 2,781
SOUN 68,351
DNN 22,882
ACON 9,638
RVPH 2,616
KOS 9,489
TNXP 107,862
SPRC 8,503
HIMS 15,980
ITRM 3,082

Vanda Pharmaceuticals Inc.

TickerCurrent Price% Daily ChangeVolume (1,000s)Average Volumn (1,000s)Market Cap (Millions)1/2/2024 Price% Change Since Inception 1/2/2024
VNDA$4.38-1.573%294602$255$4.52-3.1%
See full index: PRISM Emerging Mental Health

Contact Information

Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States

Vanda Pharmaceuticals is a biopharmaceutical company that develops and sells treatments for central nervous system disorders. The company’s goal is to improve patients’ lives by addressing unmet medical needs. Vanda’s products include:
  • Fanapt: An antipsychotic used to treat schizophrenia in adults
  • Hetlioz: A melatonin receptor agonist used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)
Vanda’s other products include Tradipitant (VLY-686), VTR-297, VQW-765, and CFTR, which are part of a portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. The company’s CEO, Mihales Polymeropoulos, MD, founded Vanda in 2003 with Care Capital LLC and Bio*One Capital. Vanda is headquartered in Washington, DC